22nd Neuronal Plasticity Prize of the Fondation Ipsen: Helen J. Neville, Isabelle Peretz and Robert J. Zatorre Awarded for Their Pioneering Research Into the Domain of "Music and Brain Plasticity"
19.7.2011 11:00:49 CEST | Business Wire | Press release
The 22nd annual Neuronal Plasticity Prize of the Fondation Ipsen has been awarded to Helen J. Neville (University of Oregon, Eugene, USA), Isabelle Peretz (Brams – University of Montreal, Montreal, Canada) and Robert J. Zatorre (Montreal Neurological Institute and Brams Laboratory, Montreal, Canada, USA) for their pioneering research in the domain of “Music and Brain Plasticity”. The €60,000 prize was awarded on July 15, 2011 by an international jury1 led by Professor Nikos Logothetis (Max Planck Institute for Biological Cybernetics, Tubingen, Germany) at the 8th International Brain Research Organization (IBRO) World Congress of Neuroscience, Florence, Italy.
About the laureates
Helen J. Neville is currently The Robert and Beverly Lewis Endowed Chair and Professor of Psychology and Neuroscience, Director of the Brain Development Lab, and Director of the Center for Cognitive Neuroscience at the University of Oregon in Eugene. Her work experience includes Director of the Laboratory for Neuropsychology at the Salk Institute. She has published in many journals such as Nature, Nature Neuroscience, Journal of Neuroscience, Journal of Cognitive Neuroscience, Cerebral Cortex and Brain Research and has made a DVD about the brain for non-scientists. She has received many honors like being elected to the American Academy of Arts and Sciences, the Board of Governors of the Cognitive Neuroscience Society, the Academic Panel of Birth to Three and is active in many educational outreach programs. She is known for her research on the role of biological constraints and experience (including music) in brain development including the study of the plasticity of auditory system.
Isabelle Peretz, Ph.D., is Professor of Psychology and the holder of a Canada Research Chair in neurocognition of music. In 2005, she became the founding co-director of the international laboratory for Brain, Music, and Sound research (BRAMS). Dr. Peretz is also the founding Editor-in-chief of Frontiers in Auditory Cognitive Neuroscience, the recipient of several awards, and a fellow of the Royal Society of Canada and of the American Psychological Association. She is renowned for her work on congenital and acquired musical disorders (amusia) and for pioneering the study of the biological foundations of music in general. Her research focuses on the musical potential of ordinary people, its neural correlates, its heritability and its specificity relative to language. She has published over 150 scientific papers on a variety of topics, ranging from perception, memory, and emotions to singing and now, dancing.
Robert J. Zatorre is a James McGill professor of neuroscience at the Montreal Neurological Institute of McGill University. Dr. Zatorre’s research explore the functional and structural organization of the human brain using neuroimaging and behavioral methods. His principal research interests relate to the neural substrate for auditory cognition, with special emphasis on two complex and characteristically human abilities: speech and music. He and his collaborators have published over 200 scientific papers on a variety of topics including pitch perception, musical imagery, absolute pitch, music and emotion, perception of auditory space, and brain plasticity in the blind and the deaf. In 2006 he co-founded the international laboratory for Brain, Music, and Sound research (BRAMS), a unique multi-university consortium dedicated to the cognitive neuroscience of music and auditory cognition.
1 Albert Aguayo (Montreal General Hospital, Montréal, Canada) , Joël Bockaert (Institut de Génomique Fonctionnelle, Montpellier, France), Alexis Brice (Hôpital de la Salpêtrière, Paris, France) , Stanlislas Dehaene (Inserm U562, Orsay, France) , Stephen Dunnett (Cardiff University, Cardiff, United Kingdom) , Kjell Fuxe (Karolinska Institute, Stockholm, Sweden) , Marc Jeannerod (Institut des Sciences Cognitives, Lyon, France) , Christine Petit (Institut Pasteur, Paris, France) , Wolf Singer (Max Planck Institute for Brain Research, Frankfurt, Germany).
About the Neuronal Plasticity Prize
Founded in 1990, the
Neuronal Plasticity Prize of the Fondation Ipsen has been awarded to
renowned specialists: Albert Aguayo (Montréal, 1990)
, Anders
Björklund (Lund, 1990),
Fred Gage (La Jolla, 1990),
Ursula
Bellugi (La Jolla, 1991),
Wolf Singer (Frankfurt, 1990),
Torsten Wiesel (New York, 1991),
Philippe Ascher (Paris, 1992),
Kjell Fuxe (Stockholm, 1992),
Terje Lomo (Oslo, 1992),
Per
Andersen (Oslo, 1993),
Masao Ito (Wako Saitama, 1993),
Constantino
Sotelo (Paris, 1993),
Mariano Barbacid (Princeton, 1994),
Yves
Barde (Planegg-Martinsried, 1994),
Hans Thoenen (Planegg-Martinsried,
1994),
Jacques Mehler (Paris, 1995),
Brenda Milner (Montreal,
1995),
Mortimer Mishkin (Bethesda, 1995),
Friedrich
Bonhoeffer (Tubingen, 1996),
Corey Goodman (Berkeley, 1996),
Marc
Tessier-Lavigne (San Francisco, 1996),
Antonio Damasio (Iowa
City, 1997),
Richard Frackowiac (London, 1997),
Michael
Merzenich (San Francisco, 1997),
Heinrich Betz (Frankfurt,
1998),
Gerald Fischbach (Boston, 1998),
Uel McMahan (Stanford,
1998),
Masakazu Konishi (Pasadena, 1999),
Peter Marler (Davis,
1999),
Fernando Nottebohm (Millbrook, 1999),
Tomas Hökfelt (Stockholm,
2000),
Lars Olson (Stockholm, 2000),
Lars Terenius (Stockholm,
2000),
Albert Galaburda (Boston, 2001),
John Morton (Londres,
2001),
Elisabeth Spelke (Cambridge, USA, 2001),
Arturo
Alvarez-Buylla (San Francisco, 2002),
Ronald Mc Kay (Bethesda,
2002),
Sam Weiss (Calgary, 2002),
François Clarac (Marseille,
2003),
Sven Grillner (Stockholm, 2003),
Serge Rossignol (Montréal,
2003),
James Gusella (Boston, 2004),
Jean-Louis Mandel (Strasbourg,
2004),
Huda Y. Zoghbi (Houston, 2004),
Ann Graybiel (Cambridge,
USA, 2005),
Trevor Robbins (Cambridge, UK, 2005),
Wolfram
Schultz (Cambridge, UK, 2005,
Eckhart D. Gundelfinger (Magdeburg,
2006)
, Mary B. Kennedy (Pasadena, 2006)
, Morgan Sheng (Cambridge,
USA, 2006),
Nikos K. Logothetis (Tübingen, 2007),
Keiji
Tanaka (Wako, 2007)
, Giacomo Rizzolati (Parma, 2007),
Jean-Pierre
Changeux (Paris, 2008)
, Peter W. Kalivas (Charleston 2008),
Eric
J. Nestler (Dallas, 2008)
, Alim-Louis Benabid (Grenoble, 2009)
,
Apostolos P. Georgopoulos (Minneapolis, 2009)
, Miguel A. L.
Nicolelis (Durham, 2009), Thomas Insel (Bethesda, 2010), Bruce Mc
Ewen (New York, 2010) and Donald Pfaff (New York, 2010).
La Fondation Ipsen
Established in 1983 under the
aegis of the Fondation de France
, the mission of the Fondation
Ipsen
is to contribute to the development and dissemination of
scientific knowledge. The long-standing action of the Fondation Ipsen
aims
at fostering the interaction between researchers and clinical
practitioners, which is indispensable due to the extreme specialisation
of these professions. The ambition of the Fondation Ipsen
is to
initiate a reflection about the major scientific issues of the
forthcoming years. It has developed an important international network
of scientific experts who meet regularly at meetings known as Colloques
Médecine et Recherche
, dedicated to six main themes: Alzheimer's
disease, neurosciences, longevity, endocrinology, the vascular system
and cancer science. Moreover, in 2007, the Fondation Ipsen
started
three new series of meetings. The first series is an annual meeting
organized in partnership with the Salk Institute and Nature
and
focuses on Biological Complexity; the second series is the “Emergence
and Convergence” series with Nature
, and the third with Cell
and
the Massachusetts General Hospital entitled “Exciting Biologies”. Since
its beginning, the Fondation Ipsen
has organised more than 100
international conferences, published 70 volumes with renowned publishers
and 216 issues of a widely distributed bimonthly newsletter Alzheimer
Actualités
. It has also awarded more than 100 prizes and grants.
Contact:
Isabelle de Segonzac, Image Sept
E-mail : isegonzac@image7.fr
Tel.
: +33 (0)1 53 70 74 70
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
